Eltjona Mane
Overview
Explore the profile of Eltjona Mane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boehm K, El Nahhas O, Marra A, Waters M, Jee J, Braunstein L, et al.
Nat Commun
. 2025 Mar;
16(1):2106.
PMID: 40025017
The Oncotype DX® Recurrence Score (RS) is an assay for hormone receptor-positive early breast cancer with extensively validated predictive and prognostic value. However, its cost and lag time have limited...
2.
Valenza C, Trapani D, Porta F, Olmeda E, Gaeta A, Boscolo Bielo L, et al.
Oncologist
. 2025 Feb;
30(2).
PMID: 39921370
Background: In patients with phyllodes tumors of the breast, the presence of mediator of RNA polymerase II transcription subunit 12 homolog mutations (MED12m) and a history of previous fibroadenoma may...
3.
Venetis K, Frascarelli C, Boscolo Bielo L, Cursano G, Adorisio R, Ivanova M, et al.
Eur J Cancer
. 2025 Jan;
217:115233.
PMID: 39827722
Mismatch repair deficiency (MMR-d) and microsatellite instability (MSI) are prognostic and predictive biomarkers in oncology. Current testing for MMR/MSI relies on immunohistochemistry (IHC) for MMR proteins and molecular assays for...
4.
Frascarelli C, Venetis K, Marra A, Mane E, Ivanova M, Cursano G, et al.
Comput Struct Biotechnol J
. 2024 Dec;
23:4252-4259.
PMID: 39678362
The tumor suppressor is frequently mutated in hormone receptor-negative, HER2-positive breast cancer (BC), contributing to tumor aggressiveness. Traditional ancillary methods like immunohistochemistry (IHC) to assess functionality face pre- and post-analytical...
5.
Guerini-Rocco E, Venetis K, Cursano G, Mane E, Frascarelli C, Pepe F, et al.
Crit Rev Oncol Hematol
. 2024 Jun;
201:104427.
PMID: 38917944
Mutations in the estrogen receptor alpha gene (ESR1) can lead to resistance to endocrine therapy (ET) in hormone receptor-positive (HR+)/ HER2- metastatic breast cancer (MBC). ESR1 mutations can be detected...
6.
Ivanova M, Pescia C, Trapani D, Venetis K, Frascarelli C, Mane E, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893102
Effective risk assessment in early breast cancer is essential for informed clinical decision-making, yet consensus on defining risk categories remains challenging. This paper explores evolving approaches in risk stratification, encompassing...
7.
Venetis K, Pescia C, Cursano G, Frascarelli C, Mane E, De Camilli E, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38891906
Multigene prognostic genomic assays have become indispensable in managing early breast cancer (EBC), offering crucial information for risk stratification and guiding adjuvant treatment strategies in conjunction with traditional clinicopathological parameters....
8.
Pepe F, Venetis K, Cursano G, Frascarelli C, Pisapia P, Vacirca D, et al.
Pharmacogenomics
. 2024 Mar;
25(3):161-169.
PMID: 38440825
gene mutations occur in approximately 40% of hormone receptor-positive/HER2-negative (HR/HER2) metastatic breast cancers (MBCs), electing them to targeted therapy. Testing status is complex due to selection of biological specimen and...
9.
Venetis K, Pepe F, Pescia C, Cursano G, Criscitiello C, Frascarelli C, et al.
Cancer Treat Rev
. 2023 Oct;
121:102642.
PMID: 37864956
Activating mutations of the estrogen receptor alpha gene (ESR1) are common mechanisms of endocrine therapy (ET) resistance in hormone receptor-positive (HR + )/Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic...
10.
Frascarelli C, Bonizzi G, Musico C, Mane E, Cassi C, Guerini Rocco E, et al.
J Pers Med
. 2023 Sep;
13(9).
PMID: 37763157
Background: Biobanks are vital research infrastructures aiming to collect, process, store, and distribute biological specimens along with associated data in an organized and governed manner. Exploiting diverse datasets produced by...